Patents by Inventor Ding-Quan Qian

Ding-Quan Qian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bipyrazole derivatives as JAK inhibitors
    Patent number: 12247020
    Abstract: The present invention provides compounds of Formula I: or pharmaceutically acceptable salts thereof, as well as their compositions and methods of use, that inhibit the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
    Type: Grant
    Filed: January 2, 2024
    Date of Patent: March 11, 2025
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Yun-Long Li, Jincong Zhuo, Ding-Quan Qian, Song Mei, Ganfeng Cao, Yongchun Pan, Qun Li, Zhongjiang Jia
  • Bicyclic DGK Inhibitors
    Publication number: 20250066363
    Abstract: The present application provides bicyclic compounds that modulate the activity of diacylglycerol kinase (DGK), which are useful in the treatment of various diseases, including cancer.
    Type: Application
    Filed: August 23, 2024
    Publication date: February 27, 2025
    Inventors: Joshua Hummel, Liana Hie, Jacob J. Lacharity, Xiaolei Li, Ding-Quan Qian, Xiaozhao Wang, Bo Wei
  • BICYCLIC AMINES AS CDK2 INHIBITORS
    Publication number: 20240415840
    Abstract: The present application provides bicyclic amines of Formula (I): and their pharmaceutically acceptable salts thereof, that are inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
    Type: Application
    Filed: June 7, 2024
    Publication date: December 19, 2024
    Inventors: Joshua Hummel, Ding-Quan Qian, Xiaozhao Wang, Ming Xiang, Meizhong Xu
  • Imidazotriazines and imidazopyrimidines as kinase inhibitors
    Patent number: 12084449
    Abstract: The present invention is directed to imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.
    Type: Grant
    Filed: January 13, 2022
    Date of Patent: September 10, 2024
    Assignees: INCYTE HOLDINGS CORPORATION, INCYTE CORPORATION
    Inventors: Jincong Zhuo, Meizhong Xu, Chunhong He, Colin Zhang, Ding-Quan Qian, David M. Burns, Yun-Long Li, Brian Metcalf, Wenqing Yao
  • BICYCLIC AMINES AS CDK2 INHIBITORS
    Publication number: 20240174664
    Abstract: The present application provides bicyclic amines that are inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
    Type: Application
    Filed: November 1, 2023
    Publication date: May 30, 2024
    Inventors: Yingda Ye, Zhenwu Li, Ding-Quan Qian, Sarah Winterton, Kaijiong Xiao, Liangxing Wu, Wenqing Yao, Joshua Hummel, Meizhong Xu, Min Ye, Yingnan Chen, Margaret Favata, Yvonne Lo
  • Bicyclic pyrazolyl amines as CDK2 inhibitors
    Patent number: 11981671
    Abstract: The present application provides bicyclic amines of Formula (I): or a pharmaceutically acceptable salt thereof, that are inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
    Type: Grant
    Filed: June 21, 2022
    Date of Patent: May 14, 2024
    Assignee: Incyte Corporation
    Inventors: Joshua Hummel, Jingwei Li, Ding-Quan Qian, Liangxing Wu
  • BIPYRAZOLE DERIVATIVES AS JAK INHIBITORS
    Publication number: 20240150327
    Abstract: The present invention provides compounds of Formula I: or pharmaceutically acceptable salts thereof, as well as their compositions and methods of use, that inhibit the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
    Type: Application
    Filed: January 2, 2024
    Publication date: May 9, 2024
    Inventors: Yun-Long Li, Jincong Zhuo, Ding-Quan Qian, Song Mei, Ganfeng Cao, Yongchun Pan, Qun Li, Zhongjiang Jia
  • Bicyclic amines as CDK2 inhibitors
    Patent number: 11976073
    Abstract: The present application provides bicyclic amines of Formula (I): and their pharmaceutically acceptable salts thereof, that are inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
    Type: Grant
    Filed: December 9, 2022
    Date of Patent: May 7, 2024
    Assignee: Incyte Corporation
    Inventors: Joshua Hummel, David M. Burns, Ding-Quan Qian, Xiaozhao Wang
  • TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS
    Publication number: 20240083898
    Abstract: The present application provides tricyclic triazolo compounds that modulate the activity of diacylglycerol kinase (DGK), which are useful in the treatment of various diseases, including cancer.
    Type: Application
    Filed: August 11, 2023
    Publication date: March 14, 2024
    Inventors: Joshua Hummel, Ding-Quan Qian, Xiaozhao Wang, Meizhong Xu
  • Bipyrazole derivatives as JAK inhibitors
    Patent number: 11905275
    Abstract: The present invention provides compounds of Formula I: or pharmaceutically acceptable salts thereof, as well as their compositions and methods of use, that inhibit the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
    Type: Grant
    Filed: January 24, 2023
    Date of Patent: February 20, 2024
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Yun-Long Li, Jincong Zhuo, Ding-Quan Qian, Song Mei, Ganfeng Cao, Yongchun Pan, Qun Li, Zhongjiang Jia
  • Bicyclic amines as CDK2 inhibitors
    Patent number: 11851426
    Abstract: The present application provides bicyclic amines that are inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
    Type: Grant
    Filed: October 9, 2020
    Date of Patent: December 26, 2023
    Assignee: Incyte Corporation
    Inventors: Yingda Ye, Zhenwu Li, Ding-Quan Qian, Sarah Winterton, Liangxing Wu, Wenqing Yao
  • TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS
    Publication number: 20230399342
    Abstract: The present application provides tricyclic triazolo compounds that modulate the activity of diacylglycerol kinase (DGK), which are useful in the treatment of various diseases, including cancer.
    Type: Application
    Filed: June 7, 2023
    Publication date: December 14, 2023
    Inventors: Joshua Hummel, Liana Hie, Jacob J. Lacharity, Xiaolei Li, Sharada Manns, Ding-Quan Qian, Xiaozhao Wang, Bo Wei, Meizhong Xu
  • IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS
    Publication number: 20230357255
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.
    Type: Application
    Filed: April 13, 2023
    Publication date: November 9, 2023
    Inventors: Xiaozhao Wang, Pei Gan, Taisheng Huang, Chao Qi, Ding-Quan Qian, Liangxing Wu, Wenqing Yao, Zhiyong Yu, Fenglei Zhang, Le Zhao, Chunhong He
  • HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
    Publication number: 20230226062
    Abstract: Disclosed are compounds of Formula (I?), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds inhibit PD-1/PD-L1 interaction and are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: September 26, 2022
    Publication date: July 20, 2023
    Inventors: Liangxing Wu, Ding-Quan Qian, Liang Lu, Neil Lajkiewicz, Leah C. Konkol, Zhenwu Li, Fenglei Zhang, Jingwei Li, Haisheng Wang, Meizhong Xu, Kaijiong Xiao, Wenqing Yao
  • BICYCLIC AMINES AS CDK2 INHIBITORS
    Publication number: 20230192706
    Abstract: The present application provides bicyclic amines of Formula (I): and their pharmaceutically acceptable salts thereof, that are inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
    Type: Application
    Filed: December 9, 2022
    Publication date: June 22, 2023
    Inventors: Joshua Hummel, David M. Burns, Ding-Quan Qian, Xiaozhao Wang, Ming Xiang, Jingwei Li
  • BICYCLIC AMINES AS CDK2 INHIBITORS
    Publication number: 20230183250
    Abstract: The present application provides bicyclic amines of Formula (I): and their pharmaceutically acceptable salts thereof, that are inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
    Type: Application
    Filed: December 9, 2022
    Publication date: June 15, 2023
    Inventors: Joshua Hummel, David M. Burns, Ding-Quan Qian, Xiaozhao Wang
  • Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
    Patent number: 11673894
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.
    Type: Grant
    Filed: October 22, 2020
    Date of Patent: June 13, 2023
    Assignee: Incyte Corporation
    Inventors: Xiaozhao Wang, Pei Gan, Taisheng Huang, Chao Qi, Ding-Quan Qian, Liangxing Wu, Wenqing Yao, Zhiyong Yu, Fenglei Zhang, Le Zhao, Chunhong He
  • Heterocyclic compounds as immunomodulators
    Patent number: 11673883
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Grant
    Filed: October 5, 2020
    Date of Patent: June 13, 2023
    Assignee: Incyte Corporation
    Inventors: Liang Lu, Ding-Quan Qian, Liangxing Wu, Wenqing Yao
  • Bicyclic heterocycles as FGFR4 inhibitors
    Patent number: 11667635
    Abstract: The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR4 enzyme and are useful in the treatment of FGFR4-associated diseases such as cancer.
    Type: Grant
    Filed: April 23, 2021
    Date of Patent: June 6, 2023
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Liang Lu, Liangxing Wu, Ding-Quan Qian, Wenqing Yao
  • BIPYRAZOLE DERIVATIVES AS JAK INHIBITORS
    Publication number: 20230159501
    Abstract: The present invention provides compounds of Formula I: or pharmaceutically acceptable salts thereof, as well as their compositions and methods of use, that inhibit the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
    Type: Application
    Filed: January 24, 2023
    Publication date: May 25, 2023
    Inventors: Yun-Long Li, Jincong Zhuo, Ding-Quan Qian, Song Mei, Ganfeng Cao, Yongchun Pan, Qun Li, Zhongjiang Jia